InflaRx: Gohibic's Niche Position Fails to Impress, INF904 Underwhelms, Cash Burn Accelerates.

InflaRx's stock has declined since my last review in April 2023 due to the company's worsening financial situation and disappointing performance of its treatments. The FDA granted Emergency Use Authorization for Gohibic, but it remains a niche treatment, while INF904 underwhelmed in clinical trials. The cash burn has accelerated, leading to a rating downgrade.